Long-acting lenacapavir in people with multi-drug resistant HIV-1: week 52 results

被引：0
|
作者：
Ogbuagu, Onyema [1 ]
Segal-Maurer, Sorana [2 ]
Brinson, Cynthia [3 ]
Chetchotisakd, Ploenchan [4 ]
McGowan, Joseph P. [5 ]
Workowski, Kimberly [6 ]
Wang, Hui [7 ]
Margot, Nicolas [7 ]
Dvory-Sobol, Hadas [7 ]
Rhee, Martin S. [7 ]
Baeten, Jared [7 ]
Kabagambe, Samm [8 ]
Molina, Jean-Michel [9 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] New York Presbyterian Queens, Flushing, NY USA
[3] Cent Texas Clin Res, Austin, TX USA
[4] Srinagarind Hosp, Khon Kaen, Thailand
[5] North Shore Univ Hosp, Manhasset, NY USA
[6] Emory Univ, Atlanta, GA 30322 USA
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] Gilead Sci Ltd, London, England
[9] Hop St Louis, Paris, France
来源：
HIV MEDICINE | 2022年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P006
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [21] Optimal control for HIV-1 multi-drug therapy
    Magombedze, Gesham
    Garira, Winston
    Mwenje, Eddie
    Bhunu, Claver Pedzisai
    [J]. INTERNATIONAL JOURNAL OF COMPUTER MATHEMATICS, 2011, 88 (02) : 314 - 340
  • [22] A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF
    Yedidi, Ravikiran S.
    Proteasa, Gheorghe
    Martin, Philip D.
    Liu, Zhigang
    Vickrey, John F.
    Kovari, Iulia A.
    Kovari, Ladislau C.
    [J]. Journal of Molecular Graphics and Modelling, 2014, 53 : 105 - 111
  • [23] A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF
    Yedidi, Ravikiran S.
    Proteasa, Gheorghe
    Martin, Philip D.
    Liu, Zhigang
    Vickrey, John F.
    Kovari, Iulia A.
    Kovari, Ladislau C.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2014, 53 : 105 - 111
  • [24] A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF
    [J]. Kovari, Ladislau C, 1600, Elsevier Inc. (53):
  • [25] Generation of a long-acting fusion inhibitor against HIV-1
    Guo, Ye
    Zhou, Pan-Pan
    Zhang, Sen-Yan
    Fan, Xiao-Wen
    Dou, Yu-Wei
    Shi, Xuan-Ling
    [J]. MEDCHEMCOMM, 2018, 9 (07) : 1226 - 1231
  • [26] Long-acting injectable antiretroviral for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (25) : E888 - E889
  • [27] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123
  • [28] Development of potent and long-acting HIV-1 fusion inhibitors
    Chong, Huihui
    Wu, Xiyuan
    Su, Yang
    He, Yuxian
    [J]. AIDS, 2016, 30 (08) : 1187 - 1196
  • [29] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [30] Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment
    Margot, N.
    VanderVeen, L.
    Naik, V.
    Chang, S.
    Parvangada, P. C.
    Martin, R.
    Dvory-Sobol, H.
    Rhee, M.
    Callebaut, C.
    [J]. HIV MEDICINE, 2021, 22 : 4 - 4
12345